Skip to main content
Livermore
Livermore
ZHEN

First Light Asset Management, LLC

SEC CIK
0001600004
Latest filing
Aug 14, 2026

The latest 13F from First Light Asset Management, LLC covers Q2 2026 (filed Aug 14, 2026): 31 long positions worth $1.65B. The top 10 holdings make up 60.7% of the portfolio, and the largest is Neogenomics Inc (NEO) at 10.9%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
2
Est. +$52.9M
Added
17
Est. +$338.5M
Reduced
12
Est. −$121.9M
Sold out
6
Est. −$117.2M

Top 5 holdings

Share of this quarter's portfolio value

  1. NEONeogenomics Inc
    10.9%$179.2MHistory
  2. SIBNSI-BONE, Inc.
    8.1%$132.6MHistory
  3. AXGNAxogen, Inc.
    7.7%$126.9MHistory
  4. APGEApogee Therapeutics, Inc.
    7.5%$123.5MHistory
  5. PVLAPalvella Therapeutics, Inc.
    7.2%$118.0MHistory

Share of portfolio

Top 5 holdings and the other 26 positions, by share of portfolio value

  1. NEO10.9%
  2. SIBN8.1%
  3. AXGN7.7%
  4. APGE7.5%
  5. PVLA7.2%
  6. Other 26 positions58.7%

Biggest buys

New and added positions, by estimated amount bought

  1. ELVNEnliven Therapeutics, Inc.
    +$58.8MAddedHistory
  2. APGEApogee Therapeutics, Inc.
    +$46.9MAddedHistory
  3. SIBNSI-BONE, Inc.
    +$45.3MAddedHistory
  4. TRVITrevi Therapeutics, Inc.
    +$39.1MNewHistory
  5. NEONeogenomics Inc
    +$37.2MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. NEONeogenomics Inc
    +4.42 pp6.5% → 10.9%History
  2. ELVNEnliven Therapeutics, Inc.
    +3.49 pp0.7% → 4.2%History
  3. APGEApogee Therapeutics, Inc.
    +3.16 pp4.3% → 7.5%History
  4. TRVITrevi Therapeutics, Inc.
    +2.38 pp0.0% → 2.4%History
  5. SIBNSI-BONE, Inc.
    +2.00 pp6.1% → 8.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CNTACentessa Pharmaceuticals plc
    −$62.0MSold outHistory
  2. AXGNAxogen, Inc.
    −$57.9MReducedHistory
  3. PVLAPalvella Therapeutics, Inc.
    −$31.9MReducedHistory
  4. TWSTTwist Bioscience Corp
    −$15.5MReducedHistory
  5. WVEWave Life Sciences, Inc.
    −$13.4MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CNTACentessa Pharmaceuticals plc
    −5.56 pp5.6% → 0.0%History
  2. AXGNAxogen, Inc.
    −4.17 pp11.9% → 7.7%History
  3. PVLAPalvella Therapeutics, Inc.
    −3.79 pp11.0% → 7.2%History
  4. WVEWave Life Sciences, Inc.
    −1.20 pp1.2% → 0.0%History
  5. VERAVera Therapeutics, Inc.
    −1.13 pp1.1% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.65B
+$529.4M (+47.4%) vs. prior quarter
Positions
31
−4 vs. prior quarter
Top 10 concentration
60.7%
Top 10 as share of value
Turnover
17.3%
Q2 2026, one quarter
Average holding period
10.5 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $1.67B (Q2 2021)

Q1 2021: $1.51BQ2 2021: $1.67BQ3 2021: $1.52BQ4 2021: $1.40BQ1 2022: $1.13BQ2 2022: $859.4MQ3 2022: $988.1MQ4 2022: $1.08BQ1 2023: $1.11BQ2 2023: $1.28BQ3 2023: $1.05BQ4 2023: $1.24BQ1 2024: $1.31BQ2 2024: $1.14BQ3 2024: $1.20BQ4 2024: $1.05BQ1 2025: $875.7MQ2 2025: $771.3MQ3 2025: $1.06BQ4 2025: $1.31BQ1 2026: $1.12BQ2 2026: $1.65B
Q1 2021Q2 2026
13F filings of First Light Asset Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202631$1.65BNEOSIBNAXGNvs. Q1 2026SEC
Q1 2026May 15, 202635$1.12BAXGNPVLANEOvs. Q4 2025SEC
Q4 2025Feb 17, 202633$1.31BAXGNNEOSIBNvs. Q3 2025SEC
Q3 2025Nov 14, 202541$1.06BAXGNPHLTCNTAvs. Q2 2025SEC
Q2 2025Aug 14, 202538$771.3MANABCNTAPHLTvs. Q1 2025SEC
Q1 2025May 15, 202537$875.7MANABAXGNCNTAvs. Q4 2024SEC
Q4 2024Feb 14, 202536$1.05BFNACNTAAXGNvs. Q3 2024SEC
Q3 2024Nov 14, 202438$1.20BCNTAFNAEVHvs. Q2 2024SEC
Q2 2024Aug 14, 202444$1.14BFNAATECCRNXvs. Q1 2024SEC
Q1 2024May 15, 202450$1.31BCRNXATECNTRAvs. Q4 2023SEC
Q4 2023Feb 14, 202475$1.24BKRTXATECXENEvs. Q3 2023SEC
Q3 2023Nov 14, 202375$1.05BPRTAATRCSIBNvs. Q2 2023SEC
Q2 2023Aug 14, 202379$1.28BRETAPRTAATRCvs. Q1 2023SEC
Q1 2023May 15, 202374$1.11BRETAPRTAMODNvs. Q4 2022SEC
Q4 2022Feb 14, 202374$1.08BMODNPRTARETAvs. Q3 2022SEC
Q3 2022Nov 14, 202271$988.1MPRTAMODNATRCvs. Q2 2022SEC
Q2 2022Aug 12, 202271$859.4MMODNATRCPRTAvs. Q1 2022SEC
Q1 2022May 13, 202275$1.13BATRCSPNEMODNvs. Q4 2021SEC
Q4 2021Feb 14, 202279$1.40BSPNEPRTAMODNvs. Q3 2021SEC
Q3 2021Nov 12, 202183$1.52BPRTASPNEMODNvs. Q2 2021SEC
Q2 2021Aug 13, 202179$1.67BSPNEPRTAHALOvs. Q1 2021SEC
Q1 2021May 17, 202177$1.51BSPNEHALOCDNA–SEC

13D and 13G filings

Companies where First Light Asset Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

11 companies, largest stake first.

Companies where First Light Asset Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
SIBNSI-BONE, Inc.13G/A18.36%8.12M shares+6.44 ppfrom 11.92%Feb 14, 20235 filingsMay 7, 2026SEC
HCATHealth Catalyst, Inc.13D/A18.30%13.5M shares−1.38 ppfrom 19.68%Nov 14, 20246 filingsMar 13, 2026SEC
MASS908 Devices Inc.13G/A17.09%6.18M shares+4.16 ppfrom 12.93%Nov 14, 20253 filingsFeb 17, 2026SEC
PHLTPerformant Healthcare Inc13G/A16.36%12.9M shares–Feb 14, 20225 filingsAug 14, 2025SEC
SLPSimulations Plus, Inc.13G13.15%2.65M sharesNewFeb 6, 20261 filingFeb 6, 2026SEC
NPCENeuroPace Inc13G/A12.25%4.20M shares+3.58 ppfrom 8.67%May 15, 20262 filingsSep 4, 2026SEC
TLSITriSalus Life Sciences, Inc.13G/A10.74%6.60M shares+1.99 ppfrom 8.75%May 15, 20262 filingsJul 7, 2026SEC
NEONeogenomics Inc13G/A8.37%10.8M shares−2.45 ppfrom 10.82%Aug 14, 20253 filingsAug 14, 2026SEC
KRMDKORU Medical Systems, Inc.13G/A8.27%3.83M shares−2.19 ppfrom 10.46%Jan 8, 20217 filingsFeb 17, 2026SEC
AXGNAxogen, Inc.13G/A7.58%4.07M shares+0.78 ppfrom 6.80%Feb 16, 20218 filingsAug 14, 2026SEC
PVLAPalvella Therapeutics, Inc.13G/A5.34%769.1K shares−2.15 ppfrom 7.49%Feb 17, 20262 filingsAug 14, 2026SEC

Latest filings

87 filings on file made by First Light Asset Management, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by First Light Asset Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
NPCENeuroPace IncSep 4, 20264:45 PM ET13G/A12.25%4.20M shares+3.58 ppfrom 8.67%Aug 31, 2026SEC
NEONeogenomics IncAug 14, 20264:35 PM ET13G/A8.37%10.8M shares−2.45 ppfrom 10.82%Jun 30, 2026SEC
AXGNAxogen, Inc.Aug 14, 20264:33 PM ET13G/A7.58%4.07M shares+0.78 ppfrom 6.80%Jun 30, 2026SEC
PVLAPalvella Therapeutics, Inc.Aug 14, 20264:33 PM ET13G/A5.34%769.1K shares−2.15 ppfrom 7.49%Jun 30, 2026SEC
TLSITriSalus Life Sciences, Inc.Jul 7, 20264:39 PM ET13G/A10.74%6.60M shares+1.99 ppfrom 8.75%Jun 30, 2026SEC
TLSITriSalus Life Sciences, Inc.May 15, 20264:44 PM ET13G8.75%5.37M sharesNewMar 31, 2026SEC
NPCENeuroPace IncMay 15, 20264:41 PM ET13G8.67%2.96M sharesNewMar 31, 2026SEC
NEONeogenomics IncMay 7, 20264:34 PM ET13G/A10.82%14.1M shares+3.25 ppfrom 7.57%Apr 30, 2026SEC
AXGNAxogen, Inc.May 7, 20264:32 PM ET13G/A6.80%3.62M shares−6.08 ppfrom 12.88%Apr 30, 2026SEC
SIBNSI-BONE, Inc.May 7, 20264:30 PM ET13G/A18.36%8.12M shares+6.44 ppfrom 11.92%Apr 30, 2026SEC
HCATHealth Catalyst, Inc.Mar 13, 20268:09 PM ET13D/A18.30%13.5M shares−1.38 ppfrom 19.68%Mar 12, 2026SEC
MASS908 Devices Inc.Feb 17, 20264:35 PM ET13G/A17.09%6.18M shares+4.16 ppfrom 12.93%Dec 31, 2025SEC
PVLAPalvella Therapeutics, Inc.Feb 17, 20264:34 PM ET13G7.49%887.0K sharesNewDec 31, 2025SEC
ORGOOrganogenesis Holdings Inc.Feb 17, 20264:34 PM ET13G/A3.06%3.89M shares−3.49 ppfrom 6.55%Below 5%Dec 31, 2025SEC
KRMDKORU Medical Systems, Inc.Feb 17, 20264:33 PM ET13G/A8.27%3.83M shares−2.19 ppfrom 10.46%Dec 31, 2025SEC
SLPSimulations Plus, Inc.Feb 6, 20264:39 PM ET13G13.15%2.65M sharesNewJan 31, 2026SEC
SIBNSI-BONE, Inc.Dec 5, 20254:32 PM ET13G11.92%5.17M shares–Nov 30, 2025SEC
MASS908 Devices Inc.Dec 5, 20254:32 PM ET13G/A12.93%4.68M shares+3.09 ppfrom 9.84%Nov 30, 2025SEC
HCATHealth Catalyst, Inc.Dec 3, 20254:03 PM ET13D19.68%13.9M shares−0.07 ppfrom 19.75%Dec 1, 2025SEC
HCATHealth Catalyst, Inc.Nov 14, 20254:41 PM ET13G/A19.75%14.0M shares+2.57 ppfrom 17.18%Sep 30, 2025SEC